ANTIVIRAL RESEARCH
Scope & Guideline
Transforming Understanding of Viral Challenges
Introduction
Aims and Scopes
- Antiviral Drug Development:
Research dedicated to the identification and characterization of new antiviral agents, including small molecules, monoclonal antibodies, and vaccines, aimed at various viral infections. - Viral Pathogenesis and Immunology:
Investigation into the mechanisms of viral replication, host interactions, and immune responses to viral infections, providing insights that inform therapeutic strategies. - Vaccine Research and Development:
Studies focused on the design, efficacy, and safety of vaccines against viral pathogens, including innovative delivery systems and adjuvants. - Genetic and Molecular Virology:
Research on the genetic and molecular basis of viral pathogenesis, including studies on viral genome structure, replication mechanisms, and resistance to antiviral agents. - Clinical Research and Epidemiology:
Studies that evaluate the clinical outcomes of antiviral treatments and the epidemiology of viral infections, providing data to guide public health interventions. - Emerging and Re-emerging Viral Infections:
Research targeting newly identified viruses and variants, emphasizing the importance of surveillance and rapid response to emerging viral threats.
Trending and Emerging
- COVID-19 and SARS-CoV-2 Research:
A surge in studies related to SARS-CoV-2, including vaccine development, therapeutic interventions, and understanding viral mutations, has become a dominant theme following the pandemic. - Host-Directed Therapies:
Research on targeting host factors to inhibit viral replication is emerging as a promising strategy, showcasing the potential of host-directed antiviral therapies. - mRNA Technology in Antiviral Vaccines:
The success of mRNA vaccines against COVID-19 has sparked interest in using mRNA technology for other viral infections, leading to innovative vaccine designs. - Broad-Spectrum Antivirals:
Increased focus on developing agents that can target multiple viruses or viral families, driven by the need for preparedness against future pandemics. - Nanotechnology in Antiviral Applications:
Emerging use of nanotechnology for drug delivery systems and vaccine platforms is gaining traction, enhancing the efficacy and reach of antiviral therapies. - Artificial Intelligence in Drug Discovery:
The application of AI and machine learning in identifying potential antiviral agents and understanding viral-host interactions is becoming increasingly prevalent.
Declining or Waning
- Traditional Antiviral Agents:
Research on older antiviral drugs has diminished, as the field shifts focus towards novel therapeutics and combination therapies that address resistance issues. - Non-specific Immunomodulators:
Interest in broad-spectrum non-specific immunomodulatory agents appears to be waning, with a greater emphasis placed on targeted therapies and precision medicine approaches. - In vitro Studies with Limited Clinical Relevance:
There is a noticeable reduction in studies that rely solely on in vitro models without clear translational applications, as the field increasingly values research that bridges laboratory findings with clinical outcomes. - Viral Resistance Mechanisms:
While still important, the frequency of publications specifically focused on mechanisms of resistance in established antiviral therapies has decreased, potentially reflecting advancements in understanding and addressing these issues.
Similar Journals
Virology Journal
Advancing the frontiers of virology research.Virology Journal, published by BMC, stands as a prominent open-access platform since 2004, dedicated to advancing the field of virology and infectious diseases. With its E-ISSN: 1743-422X, this journal is based in the United Kingdom and strives to disseminate high-quality research that enhances our understanding of viral pathogens and their interactions with hosts. Recognized with a Q1 classification in the category of Infectious Diseases and a Q2 in Virology for 2023, Virology Journal holds significant standing in the academic community, ranking #82/344 in Medicine - Infectious Diseases and #26/80 in Immunology and Microbiology - Virology. Its commitment to open access ensures that cutting-edge research is freely available to researchers, professionals, and students worldwide, fostering collaboration and innovation in the fight against viral diseases. The journal aims to publish original research articles, reviews, and commentaries that will stimulate discourse and spark new ideas within the virology community.
Journal of Virus Eradication
Innovating solutions for global virus eradication.Welcome to the Journal of Virus Eradication, a premier publication dedicated to advancing the field of virology and infectious disease research. Published by MEDISCRIPT LTD, this journal provides a vital platform for sharing cutting-edge research findings in key areas including epidemiology, immunology, and public health. With an impressive classification of Q2 in Epidemiology and Infectious Diseases for 2023, this journal exemplifies a commitment to high-quality scholarship and impactful research. The Journal of Virus Eradication is instrumental in disseminating knowledge that tackles viral threats, contributing to global health initiatives aimed at virus containment and eradication. Researchers, professionals, and students alike will find this journal an invaluable resource, making significant contributions to the scientific community and society at large.
Viruses-Basel
Elevating Knowledge in Virology and Public HealthViruses-Basel, published by MDPI, is a leading interdisciplinary journal focused on the field of virology and infectious diseases, offering a platform for the rapid dissemination of high-quality research. Established in 2009, this open access journal has become an essential resource for researchers and health professionals, ensuring that critical findings are readily available to a global audience. With an impressive Q1 ranking in Infectious Diseases and a Q2 ranking in Virology as of 2023, the journal reflects its commitment to impactful research, validated by its notable positions within Scopus categories—ranked #84 out of 344 in Medicine: Infectious Diseases and #27 out of 80 in Immunology and Microbiology: Virology. The journal adheres to high standards of academic rigor, and by embracing an open access model, it promotes unrestricted access to scientific knowledge, fostering collaboration among researchers, professionals, and students alike. Situated in Basel, Switzerland, the journal serves as a cornerstone in the dissemination of research findings related to viral diseases and their implications on public health.
ACTA VIROLOGICA
Illuminating the complexities of virology since 1957.ACTA VIROLOGICA, a key journal in the field of virology and infectious diseases, is published by FRONTIERS MEDIA SA in Slovakia, serving the global scientific community with groundbreaking research since its inception in 1957. This esteemed journal, identified by ISSN 0001-723X and E-ISSN 1336-2305, provides a platform for rigorous peer-reviewed articles that contribute significantly to our understanding of viral pathogens and their implications in medicine. Positioned within the Q3 category for both Infectious Diseases and Miscellaneous Medicine, and a Q4 category for Virology in 2023, ACTA VIROLOGICA offers crucial insights into the evolving landscape of virology research. With its robust accessibility options, this journal appeals to a diverse readership, including researchers, healthcare professionals, and students, fostering a collaborative environment to advance the field of virology. The editorial objective is to enhance the catalog of knowledge pertaining to viruses, promoting innovative approaches in prevention, diagnostics, and treatment. Located at AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE CH-1015, SWITZERLAND, ACTA VIROLOGICA continues to be a vital resource in the collective efforts to combat viral disease challenges.
Annual Review of Virology
Empowering researchers with in-depth analyses in virology.Annual Review of Virology is a premier scholarly journal published by Annual Reviews, dedicated to advancing the field of virology through comprehensive and insightful reviews. Since its inception in 2014, this journal has established itself as a leading resource for researchers, professionals, and students alike, achieving an impressive Q1 ranking in the field of Virology and a Scopus rank of #10 out of 80 in its category, placing it in the 88th percentile. The journal features in-depth analyses of the latest developments in virology, encompassing various aspects such as viral pathogenesis, host interactions, and antiviral strategies, thereby catering to a diverse audience seeking the most relevant and cutting-edge information. Although it is not Open Access, Annual Review of Virology remains an indispensable tool for those engaged in virology research, transforming complex findings into accessible knowledge that shapes future investigations and practical applications in the field.
Future Virology
Advancing the Frontiers of Viral ResearchFuture Virology, published by Future Medicine Ltd, is an essential journal dedicated to advancing the understanding of virology in the contemporary scientific landscape. With an ISSN of 1746-0794 and an E-ISSN of 1746-0808, this journal serves as a platform for researchers and practitioners in the field to publish high-quality, peer-reviewed articles that explore novel discoveries, innovative therapeutic strategies, and the implications of viral research on global health. Operating from the United Kingdom and maintaining a commitment to rigorous scientific inquiry, Future Virology is categorized in the Q4 Quartile for Virology according to the latest Scopus rankings, with a position of Rank #48/80 and a percentile of 40th in the Virology category. Although it currently does not offer open access, the journal strives to disseminate critical insights that benefit a wide range of professionals, researchers, and students engaged in virology and related fields. By bridging the gap between basic research and practical applications, Future Virology plays a crucial role in fostering innovation and collaboration in the ever-evolving virology landscape.
JOURNAL OF VIROLOGICAL METHODS
Enhancing understanding through rigorous virological methods.Journal of Virological Methods, published by Elsevier, is a prominent peer-reviewed journal dedicated to advancing the methodologies employed in virology research. Since its inception in 1980, this esteemed journal has become a vital resource for researchers, professionals, and students focused on the intricate study of viruses and viral-related diseases. With a current ISSN of 0166-0934 and an E-ISSN of 1879-0984, this journal strives to present innovative techniques and tools that enhance our understanding of virology. Designed for a global audience, it operates in a rigorous academic environment, as reflected by its 2023 Scopus ranking of #40 in the Virology category and its Q3 quartile placement. The journal is committed to fostering open dialogue and collaboration within the scientific community, ultimately contributing to the development of novel strategies and interventions against viral infections. By offering comprehensive insights into virological methodologies, the Journal of Virological Methods continuously serves as a cornerstone for those dedicated to exploring the complexities of viral research.
Advances in Virology
Unlocking the Secrets of Viruses and Infectious DiseasesAdvances in Virology, an esteemed journal published by HINDAWI LTD, serves as a pivotal platform for cutting-edge research in the field of virology and infectious diseases. With its ISSN 1687-8639 and E-ISSN 1687-8647, the journal has been a significant contributor to the scientific community since its initiation as an Open Access resource in 2009, allowing researchers from around the globe to access groundbreaking findings without barriers. Operating out of the United States and recognized for its commitment to high-quality research, the journal's relevance is underscored by its ranking in the Q3 category for Infectious Diseases and Q4 for Virology as of 2023. The time frame of publications spans from 2009 to 2024, reflecting a continuous commitment to exploring the evolving landscape of virology. This journal not only promotes the dissemination of novel insights and methodologies but also fosters collaboration and innovation within the scientific community, making it an invaluable resource for researchers, professionals, and students alike.
ANTIVIRAL THERAPY
Advancing the frontier of antiviral research.ANTIVIRAL THERAPY is a prominent academic journal dedicated to the field of infectious diseases and pharmacology, published by SAGE Publications Ltd in the United Kingdom. Since its inception in 1996, this journal has become an essential platform for disseminating cutting-edge research and innovative therapeutic approaches for viral infections, making significant contributions to advancements in medical science. With an HIndex indicating the quality and influence of its published work, ANTIVIRAL THERAPY holds prestigious rankings in its categories, including Q3 in Infectious Diseases and Pharmacology as of 2023. While it currently does not offer open access, the journal provides valuable insights that are crucial for researchers, healthcare professionals, and students engaged in antiviral research and treatment strategies. As it converges towards 2024, the journal continues to play a vital role in shaping the understanding and management of viral diseases, making it a critical resource for anyone involved in this important field of study.
VIROLOGICA SINICA
Advancing the Frontiers of Virology ResearchVIROLOGICA SINICA, published by KEAI PUBLISHING LTD, is a leading international journal dedicated to the field of virology. With an ISSN of 1674-0769 and E-ISSN of 1995-820X, this esteemed journal showcases cutting-edge research from 2006 to 2024, focusing on critical developments in Immunology, Infectious Diseases, Molecular Medicine, and Virology. As evidenced by its respectable positioning in the Q2 quartile of relevant categories and impressive Scopus rankings—such as Rank #20/80 in Virology—VIROLOGICA SINICA serves as an essential resource for researchers, professionals, and students aiming to deepen their understanding of viral pathogens and their impact on human health. While the journal does not currently offer open access, it remains an invaluable publication for those seeking to stay at the forefront of virology research. Its address is located at 16 Donghuangchenggen North St, Beijing, China, where it continues to foster academic excellence in the rapidly evolving landscape of virology.